Capmatinib combined with gefitinib was shown in a phase Ib/II study to be effective in patients with EGFR-mutated, MET-amplified/overexpressed NSCLC after progressing from prior EGFR-TKI therapy, with an ORR of 47% among patients with fluorescence in situ hybridization-based MET CN of ≥6 (24). Here, MET is linked to non-small cell lung carcinoma.